

Pneumococcal Vaccines

Grace Lee, MD, MPH

Pneumococcal Vaccines Work Group Chair

Advisory Committee on Immunization Practices

February 22, 2018



Pneumococcal Vaccines Work Group

- ACIP members
 - Grace Lee (Chair)
 - Nancy Bennett
 - Paul Hunter
- Ex officio members
 - Tina Mongeau (FDA)
 - Lucia Lee (FDA)
- CDC lead
 - Tamara Pilishvili (NCIRD)
- Liaison representatives and consultants
 - Lorry Rubin (AAP)
 - Mark Sawyer (AAP/CIOD)
 - Rick Zimmerman (AAFP)
 - Chris Lupold (AAFP)
 - Sandra Fryhofer (ACP)
 - Jane Zucker (AIM)
 - William Schaffner (NFID)
 - Monica Farley (DVA)
 - Jeffrey Duchin (U. of Washington)
 - Keith Klugman (Gates Foundation)
 - Kathy Neuzil (IDSA)
 - Arthur Reingold (U of California, Berkeley)

Pneumococcal Vaccines Work Group: Terms of Reference

- Review current data on efficacy, effectiveness, immunogenicity, and cost-effectiveness of pneumococcal vaccines
- Review current recommendations considering up-to-date evidence, including epidemiological studies conducted post-licensure, and assess strength of the evidence
- Revise or update recommendations for pneumococcal vaccine use, as needed

ACIP August 2014: PCV13 recommended for adults 65 years and older

- Work Group and ACIP Conclusions
 - Short term: recommendation for universal PCV13 use is warranted
 - Long term: continued herd effects may limit the utility of a universal recommendation
 - Magnitude of indirect effects unknown
 - Uncertainty around the burden of vaccine preventable non-bacteremic pneumonia
 - Recommendation for re-evaluation and revision as needed of routine PCV13 use among adults 65 years and older

Re-evaluation of PCV13 for adults 65 years and older recommendation

- Monitor pneumococcal disease and vaccine impact among adults 65 years and older
- Monitor indirect vaccine effects on pneumococcal disease trends among PCV13-naïve adults (19-64 years old without PCV13 indications)
- Update ACIP on direct and indirect effects and pneumococcal disease trends among adults
- Use the Evidence to Recommendation (EtR) framework to re-evaluate the use of PCV13 among adults 65 year and older

October 2017 ACIP Meeting

- Updated on changes in carriage and invasive pneumococcal disease (IPD)
- Among adults ≥ 65 years old:
 - Carriage rates are very low (1.8% overall and 0.2% for PCV13 serotypes)
 - IPD caused by PCV13 serotypes declined by 40% after PCV13 was introduced in children and annual incidence rates plateaued in 2014–2016
- Presented outline of research agenda to inform potential policy change

Today's Pneumococcal Vaccines Session

Outline

- PCV13 effectiveness against IPD among adults ≥ 65 years old (Tamara Pilishvili, NCIRD)
- PCV13 direct and indirect effects among adults ≥ 65 years old (Tamara Pilishvili, NCIRD)
- PCV13 effectiveness against pneumococcal pneumonia among U.S. adults and coverage estimates (John McLaughlin, Pfizer Vaccines)
- Estimating burden of pneumococcal pneumonia among U.S. adults and progress of the research agenda to inform potential policy change (Almea Matanock, NCIRD)

Discussion Questions for Today's Pneumococcal Vaccines Session

- Is the proposed research agenda appropriate to help determine if potential policy change is needed?
- What additional information will the committee need to help determine whether continued PCV13 use in adults 65 years and older is warranted?